https://www.selleckchem.com/pr....oducts/CP-690550.htm
Objective Panel-based sequencing is widely used to measure tumor mutational burden (TM in clinical trials and is ready to enter routine diagnostics. However, cut-off points to distinguish "TMB-high" from "TMB-low" tumors are not consistent and the clinical implications of TMB in predicting responses to immune checkpoint blockade (IC in gastric cancer are not clearly defined. We aimed to assess whether TMB is associated with the response to immunotherapy and to examine its relation with other biomarkers of immunotherapy response in
Like
Comment
Share
